Condition: Metastatic Breast Cancer · HER2-positive Breast Cancer · Sponsor: UNICANCER
Heroes is a multicentre, national, non-randomized, open-label, phase 2 study. The goal of this clinical trial is to evaluate the feasibility of therapeutic de-escalation in HER2-positive metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy AND ctDNA negative testing. The main question it aims to answer is : • Is it possible to identify patients for whom temporary or permanent discontinuation of treatment is possible without impacting prognosis?
This description comes directly from the study's public registry record.
Clara Guyonneau, PharmD · +33 (0) 1 44.23.04.65 · c-guyonneau@unicancer.fr
Thibault De la Motte Rouge, MD · t.delamotterouge@rennes.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Eugène marquis | Rennes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06450314